The GANNET53 trial is the first to use ganetespib in ovarian cancer patients, to combine ganetespib with paclitaxel, and to potentially target stabilized mutant gain-of function p53 proteins via the innovative mechanism of induced depletion via Hsp90 inhibition. The gene discussed is TP53; the disease is ovarian carcinoma.